Cure Logo
LEXEO Therapeutics logo Cure Collaboration Residency

Lexeo Therapeutics

A clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated.

Cure resident Lexeo Therapeutics website hero image

Overview

Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease are treated. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimer’s disease programs.

Lexeo Therapeutics's Mission

Our mission is to transform healthcare by pushing boundaries in developing meaningful genetic medicines for diseases, regardless of prevalence. By taking aim at the underlying genetic cause of the devastating diseases we target, Lexeo seeks to create substantial positive impact and reduce the overwhelming burdens placed on people receiving treatment, their caregivers, and healthcare systems.

At-a-Glance

  • Lexeo currently has three programs in clinical trials with multiple data readouts expected in 2024.

  • Lead programs include Phase 1/2 trials of LX2006 for the treatment of Friedreich's ataxia (FA) cardiomyopathy, LX1001 for the treatment of APOE4-associated Alzheimer’s disease and LX2021 for the treatment of arrhythmogenic cardiomyopathy caused by mutations in the PKP2 gene (PKP2-ACM).

  • Building on groundbreaking research from Weill Cornell Medicine and the University of California San Diego, Lexeo partners with preeminent institutions on the cutting edge of gene therapy research.

In the News

Biotech Expert Manny Otero, PhD, on Trends Shaping Startups

José Manuel (Manny) Otero, PhD, Chief Technical Officer at Lexeo Therapeutics shares a roadmap for early-stage biotechs.

test tube liquid DNA data colors
Gene Therapy, Once Reserved for Rare Single-Gene Disorders, Finds a Place in Precision Medicine

What's ahead for gene therapy? R. Nolan Townsend, MBA, co-founded LEXEO Therapeutics to focus on bringing precision genetic medicines to patients with genetic cardiovascular diseases and Alzheimer’s.

Lexeo Applies Gene Therapy to Alzheimer’s and Heart Diseases

Lexeo Therapeutics is innovating not just genetic modifications as therapies for target diseases, but also manufacturing and clinical studies.

Lexeo Therapeutics: Revolutionizing Genetic Medicine for Cardiovascular and Neurodegenerative Diseases
Lexeo Therapeutics: Revolutionizing Genetic Medicine for Cardiovascular and Neurodegenerative Diseases

Lexeo Therapeutics is developing pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease.

Global Perspective: Top 3 Leadership Lessons from Lexeo CEO Nolan Townsend

Before he became CEO of Lexeo Therapeutics, R. Nolan Townsend, MBA, worked across Pfizer, in Finance, Corporate Strategy, Operations and Marketing, and Rare Disease in North America, Asia, Africa/Middle East and Europe. 

Start-up Financing in a Risk-Averse Climate: 3 Lessons From the COVID Years

LEXEO successfully navigated pandemic-era financing. Here are three lessons learned for successful startup financing in a challenging climate.

Next Resident

Metallomix Inc.

logo metallomix